Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 113

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 113
---
 (SLL), and the secondary endpoint is PFS.
SLL data are expected within one year following the completion of enrollment and final PFS data are expected approximately three years
following the completion of enrollment. This trial will also include a wealth of translational endpoints aimed at understanding the clonal
evolution and immunogenomic features of the MRD phase of ovarian cancer that is currently undetectable by imaging or tumor markers.

As
of March 31, 2025, fourteen patients were enrolled and treated in the study at the University of Texas MD Anderson Cancer Center and
Memorial Sloan Kettering Cancer Center. John Hopkins Medicine Sidney Kimmel Cancer Care Center has been added as a clinical site for
this study and is open to recruitment.

PLACCINE
DNA VACCINE MODALITY: IMNN-101

In
January 2021, the Company announced the filing of a provisional U.S. patent application for a novel DNA-based, investigational vaccine
for preventing or treating infections from a broad range of infectious agents including the coronavirus disease using its PLACCINE DNA
vaccine modality (“PLACCINE”). The provisional patent covers a family of novel composition of multi-cistronic vectors and
polymeric nanoparticles that comprise the PLACCINE DNA vaccine platform technology for preventing or treating infectious agents that
have the potential for global pandemics, including the SARS-CoV-2 virus and its variations, using the Company’s TheraPlas platform
technology.

Imunon’s
PLACCINE DNA vaccine modality is characterized by a single mono-cistronic or multi-cistronic DNA plasmid vector expressing single or
multiple pathogen antigens delivered with a synthetic delivery system. We believe it is adaptable to creating vaccines for a multitude
of pathogens, including emerging pathogens leading to pandemics as well as infectious diseases that have yet to be effectively addressed
with current vaccine technologies. This flexible vaccine platform is well supported by an established supply chain to produce any plasmid
vector and its assembly into a respective vaccine formulation.

The
need for new vaccine technologies is urgent. Since 1980, more than 80 pathogenic viruses have been discovered, yet fewer than 4% have
a commercially available prophylactic vaccine. We have engaged with the Biomedical Advanced Research and Development Authority (“BARDA”),
a division of the U.S. Department of Health and Human Services, to consider certain pathogens BARDA has identified as the most urgent
and the most important.

PLACC